According to Fixygen, OJSC “Research and Production Center ‘Borshchahivsky Chemical and Pharmaceutical Plant’” will hold a general meeting of shareholders on April 30, 2026, via remote participation. The agenda includes the approval of the annual financial statements, profit distribution, and operating results for 2025.
Borshchagovsky Chemical and Pharmaceutical Plant is one of Ukraine’s largest pharmaceutical manufacturers and produces a wide range of medicines for the domestic market and export.
According to Opendatabot, Borshchagovsky Chemical and Pharmaceutical Plant increased its revenue by 7.8% in 2025 compared to 2024—to 2.241 billion UAH. It was previously reported that by the end of 2024, the company had increased its net profit by nearly 17% compared to 2023—to 273.4 million UAH.
Currently, BHFZ’s shareholders include PJSC “Pharmaceutical Firm ‘Darnitsa’” (Kyiv), which owns 31.8% of the shares, as well as “Beldor Group” (21.26%) and “Lenik Group” (20.32%).
The ultimate beneficiaries of the company are Gleb Zagoriy, Yevgeniy Sova, Tatyana Artemenko, Nikolay Bezpalko, and Oleg Goloborodko.
Borshchahivsky Chemical and Pharmaceutical Plant, shareholders' meeting
